Sugi Predict

Sugi Predict / Compounds / SCHEMBL2007672

SCHEMBL2007672

SCHEMBL2007672

Cc1ccc(S(N)(=O)=O)o1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.48
▸ HTT P42858 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.46
▸ CA2 P00918 10/20 0.39
▸ CA12 O43570 2/20 0.39
▸ CA1 P00915 2/20 0.39
▸ CA9 Q16790 2/20 0.39
▸ CA3 P07451 1/20 0.39
▸ CA6 P23280 1/20 0.39
▸ CA5A P35218 1/20 0.39
▸ CA7 P43166 1/20 0.39
▸ CA5B Q9Y2D0 1/20 0.39
▸ CCR2 P41597 4/20 0.38
▸ KDM4E B2RXH2 2/20 0.36
▸ MAPT P10636 2/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ LMNA P02545 1/20 0.36
▸ GAA P10253 1/20 0.35
▸ PKM P14618 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31748021 0.82 TDP1 (0.42) ALDH1A1HTTTDP1CA2CA12
SCHEMBL10274786 0.78 CCR2 (0.50) ALDH1A1HTTTDP1CCR2MAPT
SCHEMBL3468425 0.76 TDP1 (0.46) ALDH1A1TDP1CA2CA1CCR2
SCHEMBL214431 0.76 TDP1 (0.46) ALDH1A1HTTTDP1CCR2MAPT
SCHEMBL11050586 0.74 TDP1 (0.43) ALDH1A1TDP1CA2CA1CCR2
Hydrochloric Acid SCHEMBL11049903 0.74 TDP1 (0.43) ALDH1A1TDP1CA2CA1CCR2
SCHEMBL11050566 0.74 TDP1 (0.43) ALDH1A1TDP1CA12CA9CCR2
SCHEMBL3022289 0.73 ALDH1A1 (0.50) ALDH1A1HTTCA2CA12CA1
SCHEMBL13908191 0.73 TDP1 (0.42) ALDH1A1TDP1CCR2MAPTPKM
SCHEMBL24032730 0.71 ALDH1A1 (0.44) ALDH1A1HTTTDP1CA2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101516837-A Sulfonamide derivatives HOFFMANN LA ROCHE (CH) 2009-08-26 — — CN claimed
US-20250388568-A1 NLRP3 INHIBITORS KODIAK SCIENCES INC (US) 2025-12-25 — — US disclosed
US-20240400502-A1 SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME UNIV QUEENSLAND (AU) 2024-12-05 — — US disclosed
CN-113582889-B Sulfonylureas and related compounds and uses thereof 昆士兰大学 2024-09-20 — — CN disclosed
EP-3416948-B1 INDACENE BEARING SULFONYLUREAS AS ANTI-INFLAMMATORY AGENTS UNIV QUEENSLAND (AU) 2024-07-24 — — EP disclosed
US-11858922-B2 Sulfonylureas and related compounds and use of same THE UNIVERSITY OF QUEENSLAND (AU) 2024-01-02 — — US disclosed
US-11845715-B2 — — 2023-12-19 — — US disclosed
US-11845715-B2 — — 2023-12-19 — — US disclosed
US-11845715-B2 — — 2023-12-19 — — US disclosed
CN-109071454-B Sulfonylureas and related compounds and uses thereof 昆士兰大学 2023-02-17 — — CN disclosed
WO-2016131098-A1 SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME THE UNIVERSITY OF QUEENSLAND (AU) 2016-08-25 — — WO disclosed
CN-103339132-A Novel purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against raf kinase, containing same as active ingredi YOUAI CO LTD 2013-10-02 — — CN disclosed
US-7964633-B2 such as N,N'-[hexane-1,6-diylbis(iminocarbonyl)]bis(3-chlorobenzenesulfonamide), used as Fructose-1,6-bisphosphatase inhibitors; metabolic disorders such as diabetes HOFFMANN-LA ROCHE INC. (US) 2011-06-21 — — US disclosed
EP-2081889-B1 SULFONAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-12-22 — — EP disclosed
CN-101516837-A Sulfonamide derivatives HOFFMANN LA ROCHE (CH) 2009-08-26 — — CN disclosed
EP-2081889-A1 SULFONAMIDE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2009-07-29 — — EP disclosed
US-20080085928-A1 Sulfonamide derivatives HOFFMANN-LA ROCHE INC. 2008-04-10 — — US disclosed
WO-2008037628-A1 SULFONAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-04-03 — — WO disclosed
CN-1294126-C N-phenyl-arylsulfonamide compound, drug comprising the compound as active ingredient, intermediate for the compound ONO PHARMACENTICAL CO LTD (JP) 2007-01-10 — — CN disclosed
CN-1509278-A N-phenyl-arylsulfonamide compound, drug comprising the compound as active ingredient, intermediate for the compound СҰҩƷ��ҵ��ʽ���� 2004-06-30 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11845715-B2 — NLRP3, PYCARD, NOD1 ALDH1A1 3407/4885HTT 543/4885TDP1 1954/4885
US-20240400502-A1 SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME NLRP3, PYCARD, IAPP ALDH1A1 3558/4885HTT 934/4885TDP1 2453/4885
US-11858922-B2 Sulfonylureas and related compounds and use of same NLRP3, NOD1, PYCARD ALDH1A1 1668/4885HTT 1407/4885TDP1 2296/4885
US-20250388568-A1 NLRP3 INHIBITORS NLRP3, NOD1, NLRP1 ALDH1A1 3213/4885HTT 737/4885TDP1 844/4885
US-20080085928-A1 Sulfonamide derivatives SULT2A1, SULT1A1, SULT1E1 ALDH1A1 168/4885HTT 2895/4885TDP1 3048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.